Vitrolife AB (publ) (“Vitrolife”) publishes a prospectus for the admission to trading of newly issued shares in Vitrolife on Nasdaq Stockholm's main market in connection with a non-cash issue through which Vitrolife acquires all shares in Mendel Holdco S.L. and thereby indirectly all shares in Igenomix S.L. ("Igenomix") ("The Transaction"). The transaction is described in more detail in Vitrolife's press release dated 8 July 2021. The prospectus does not contain any offer to subscribe for, or in any other way acquire shares or other financial instruments in Vitrolife, either in Sweden or in any other jurisdiction.
The transaction means that the number of shares in Vitrolife will increase by 17,251,312 shares from 118,195,878 shares to a total of 135,447,190 shares and that the share capital will increase by SEK 3,519,267.648, from SEK 24,111,959.112 to a total of SEK 27,631,226.760. The dilution for Vitrolife's existing shareholders amounts to 12.7 percent of capital and votes.
The prospectus, that has been prepared in connection with the admission to trading of the newly issued shares, has today been approved and registered by the Swedish Financial Supervisory Authority (“Finansinspektionen”). The prospectus is available on Finansinspektionen's website, www.fi.se, and Vitrolife's website, www.vitrolife.com, as well as on request in paper format.
